<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944890</url>
  </required_header>
  <id_info>
    <org_study_id>RG01W-1101</org_study_id>
    <nct_id>NCT02944890</nct_id>
  </id_info>
  <brief_title>Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Study to Compare the Efficacy and Safety of 2 Types of Drug Eluting Balloon Catheters (RESTORE DEB and SeQuent® Please) in Chinese Patient With Coronary In-stent Restenosis (ISR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZhuHai Cardionovum Medical Device Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ZhuHai Cardionovum Medical Device Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Paclitaxel drug eluting&#xD;
      balloons (RESTORE DEB, 3μg/mm2 balloon surface area ) for success of intervention treatment&#xD;
      and maintaining the vessels unobstructed in the treatment of coronary in-stent restenosis&#xD;
      compared with a product of the same category (SeQuent® Please).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late lumen loss of the target lesion</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The success rate of intervention treatment: including device success, lesion success and clinical success</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of restenosis in the target lesions</measure>
    <time_frame>9 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>1, 6, 9, and 12 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>1, 6, 9, and 12 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>1, 6, 9, and 12 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of major adverse cardiovascular events</measure>
    <time_frame>1, 6, 9, and 12 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events and severe adverse events</measure>
    <time_frame>1, 6, 9, and 12 months after the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>RESTORE DEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conduct Drug Eluting Balloon Catheters(RESTORE DEB）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SeQuent® Please</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conduct Drug Eluting Balloon Catheters(SeQuent® Please）</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Balloon Catheters(RESTORE DEB）</intervention_name>
    <arm_group_label>RESTORE DEB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Balloon Catheters(SeQuent® Please）</intervention_name>
    <arm_group_label>SeQuent® Please</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Related to the patients:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Patients agree to receive follow-ups in month-1, 6, 9 and 12, and receive angiography&#xD;
             in month-9.&#xD;
&#xD;
          3. Patients are able to understand the objectives of the study mentally and in language.&#xD;
             Patients should indicate sufficient compliance to the study, and acknowledge all risks&#xD;
             and benefits by signing the informed consent form.&#xD;
&#xD;
          4. Patients with stable angina pectoris, or unstable angina pectoris, or old myocardial&#xD;
             infarction, or proved asymptomatic regional myocardial ischemia&#xD;
&#xD;
          5. Patients suitable to receive coronary revascularization of any type (including balloon&#xD;
             angioplasty, stent implantation or coronary artery bypass grafting)&#xD;
&#xD;
             Related to the diseases:&#xD;
&#xD;
          6. Restenosis Mehran type I-III after stent implantation (including bare metal stents,&#xD;
             stents with inert coating, and stents with active coating) for the first time&#xD;
&#xD;
          7. Diameter of the stent with restenosis should be 2.5-4.0mm (included). Length of the&#xD;
             stenosis lesion should be no more than 26mm, and diameter stenosis before operation&#xD;
             should be ≥70%, or ≥50% with the evidence of ischemia.&#xD;
&#xD;
          8. One subject is allowed to have 2 target lesions at most, and 2 Paclitaxel drug&#xD;
             balloons for dilation.&#xD;
&#xD;
          9. The distance between lesions which require intervention and the target lesions must be&#xD;
             &gt;10mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Related to the patients:&#xD;
&#xD;
          1. Pregnant or lactating women, or women who plan to get pregnant within 12 months or&#xD;
             refuse to take effective contraceptives.&#xD;
&#xD;
          2. The patients are participating in any other clinical trials before reaching the&#xD;
             primary endpoints.&#xD;
&#xD;
          3. The patients have a life expectancy of less than 12 months, or it would be difficult&#xD;
             to finish follow-ups within 12 months.&#xD;
&#xD;
          4. The patients had cerebral stroke within 6 months before being included, or have a&#xD;
             history of peptic ulcer or gastrointestinal bleeding in the past 6 months, or the&#xD;
             patients have a bleeding tendency according to the investigator.&#xD;
&#xD;
          5. Patients with a history of leukopenia (white blood cell count &lt;3×109/L for more than 3&#xD;
             days) or neutropenia (ANC&lt;1000/mm3 for more than 3 days) or thrombocytopenia (platelet&#xD;
             &lt;100,000/mm3)&#xD;
&#xD;
          6. Patients who are forbidden to use anticoagulation agents or anti-platelet drugs, and&#xD;
             unable to tolerate Aspirin or Clopidogrel&#xD;
&#xD;
          7. Patients with renal insufficiency (eGFR&lt;30mL/min)&#xD;
&#xD;
          8. Patients who are known to be allergic to Paclitaxel&#xD;
&#xD;
          9. Patients who had myocardial infarction within 1 week before being included&#xD;
&#xD;
         10. Patients who had heart transplantation&#xD;
&#xD;
         11. Patients with severe congestive heart failure or NYHA grade IV heart failure&#xD;
&#xD;
         12. Patients with severe valvular heart disease&#xD;
&#xD;
         13. Patients who are unsuitable for the study according to the investigator due to other&#xD;
             reasons&#xD;
&#xD;
             Related to the diseases:&#xD;
&#xD;
         14. Patients with evidence of extensive thrombosis in the target vessel before&#xD;
             intervention&#xD;
&#xD;
         15. Patients with total occlusion indicating TIMI 0 blood flow at the target lesion&#xD;
             (Mehran type IV stenosis)&#xD;
&#xD;
         16. Patients with multiple lesions (≥3) requiring percutaneous coronary intervention&#xD;
             treatment in the same artery&#xD;
&#xD;
         17. Patients with lesions requiring intervention treatment in 3 vessels&#xD;
&#xD;
         18. The diameter of the branch lesions in the target lesion ≥2.5mm&#xD;
&#xD;
         19. Patients already treated with CABG after in-stent restenosis&#xD;
&#xD;
         20. LM lesions and Ostial lesion within 5mm to the root aorta&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital School of medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

